BioCentury
ARTICLE | Clinical News

Mereo's BGS-649 meets in Phase IIb for hypogonadism

March 23, 2018 5:17 PM UTC

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase IIb trial in 271 obese men with hypogonadotropic hypogonadism showing that all three doses of once-weekly oral BGS-649 met the primary endpoint of normalizing total testosterone levels in >75% of patients at week 24 vs. placebo (p<0.001 for all). All three doses of BGS-649 also met the secondary endpoint of improving testosterone luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels at week 24 vs. placebo (p<0.001 for all). Additionally, mid- and high-dose BGS-649 met the secondary endpoint of normalizing testosterone levels in >90% of patients at week 24 vs. placebo. Low-dose BGS-649 normalized testosterone levels in 88% of patients at week 24. BGS-649 was well tolerated in the double-blind, international trial.

Data from a six-month Phase IIb safety extension study are expected in 4Q18. BGS-649 is an oral aromatase inhibitor...

BCIQ Target Profiles

Aromatase